Single nucleotide polymorphisms (SNPs) in the NOD2 gene have significant impact on both treatment-related mortality (TRM) and acute GVHD (aGVHD) in haematopoietic stem cell transplantation (HSCT). The effect of these polymorphisms when using T-cell-depleted grafts has been poorly studied. We retrospectively analysed NOD2 polymorphisms in a cohort of 85 patients and donors who received an HLA-identical sibling partially T-cell-depleted HSCT (0.5 Â 10 6 CD3 þ T cells per kg) following idarubicin-containing conditioning regimens. NOD2 polymorphisms were present in 14 of 85 (16.5%) of patients and 18 of 85 (21%) of donors. The risk of severe aGVHD (grade III-IV) and the 1-year TRM was significantly higher in the presence of NOD2 polymorphisms (hazard ratio (HR) 6.0, P ¼ 0.02 for severe aGVHD and HR 3.3, P ¼ 0.02 for TRM, respectively) and was most prominent in cases where patient and donor both had a polymorphism (HR 10.5, P ¼ 0.002 and HR 3.9, P ¼ 0.002). There was also a trend towards increased risk of bacteraemia due to coagulasenegative staphylococci in patients with an NOD2 polymorphism. We conclude that NOD2 polymorphism screening should be used to optimize donor selection and antimicrobial prophylaxis to reduce the occurrence of aGVHD and TRM following allogeneic HSCT.
Introduction
Acute GVHD (aGVHD), infections and other inflammatory complications following conditioning therapy still have considerable impact on morbidity and mortality in haematopoietic stem cell transplantation (HSCT). An uncontrolled inflammatory response as a result of the mucosal barrier injury (MBI) by cytostatic chemotherapy and subsequent microbial translocation are thought to be important in the initiation of aGVHD. [1] [2] [3] Polymorphisms of innate immune genes (non-HLA genes) can affect the inflammatory responses and therefore the incidence of aGVHD. 4, 5 Any polymorphism that predicts complications should therefore be screened to select the most suitable stem cell donor.
A robust association between single nucleotide polymorphisms (SNPs) in NOD2/CARD15 and the outcome of allogeneic HSCT has been reported by Holler et al. 6 NOD2 is an intracytosolic pattern recognition receptor that senses muramyl dipeptide (MDP) of bacterial cell walls, and is expressed in Paneth cells, DCs, neutrophils and monocytes. 7 Altered function due to NOD2 polymorphisms can result in uncontrolled inflammation of the gut mucosa and can result in Crohn's disease. 8 The pathogenesis is not fully understood but there are several hypotheses involving the loss of antimicrobial activity and a deregulated immune response. Reduced antimicrobial activity results from decreased production of antimicrobial peptides, 9 ,10 decreased autocrine cytokine release 11 and increased gut permeability, 12 leading to bacterial translocation that elicits an immune response through toll-like receptor (TLR) signalling. This response is deregulated with increased production of Th1 and probably Th17 cytokines due to reduced inhibition of TLR-mediated cytokine release ('loss of tolerance') [13] [14] [15] [16] or decreased production of IL-10. 17 Several reports, but not all, have shown that NOD2 polymorphisms influence the evolution of aGVHD, the occurrence of treatment-related mortality (TRM), 6 the incidence of disease relapse 18 and the development of bronchiolitis obliterans. 19 This underlines the importance of the specific conditions surrounding HSCT. For instance, T-cell-depleted HSCT with delayed T-cell recovery could reduce the impact of NOD2 polymorphisms on aGVHD. Therefore, we undertook a retrospective analysis on the impact of NOD2 polymorphisms in a homogenous cohort of Dutch recipients of a partially T-cell-depleted HSCT at our hospital.
Patients, materials and methods

Patients and donors
One hundred and sixteen (n ¼ 116) Dutch patients and their donors were initially included in the study. All had participated in supportive care studies and been admitted to our transplant unit between May 1996 and November 2005 for an HLA-identical sibling, T-cell-depleted allogeneic HSCT. To obtain the most homogenous cohort possible, we selected 85 patients who had been given idarubicin in their conditioning regimen. The characteristics of patients, donors and HSCT procedures are depicted in Table 1 .
Treatment protocol
All patients had been treated according to the same protocol and received a central venous catheter (CVC). The conditioning regimen consisted of idarubicin (42 mg/kg in 48 h), CY (60 mg/kg for 2 days) and either TBI (4.5 Gy for 2 days) or BU (4 mg/kg for 4 days). Idarubicin was used in this conditioning regimen to reduce the risk of relapse in the setting of T-cell-depleted HSCT. 20 Partial T-celldepletion was achieved by counterflow elutriation, CD34 selection or CD3/CD19 depletion. On day 0, all patients were given a graft containing 3.0 Â 10 6 CD34 þ cells per kg (range 0.8-11.4; BM or PBSC) and 0.5 Â 10 6 CD3 þ cells per kg (range 0.3-0.7) achieved by dosed T-cell add back. GVHD prophylaxis consisted of CsA only.
GVHD was diagnosed by clinical signs, or pathological examination of biopsies of skin, gut or liver. GVHD was graded according to the criteria of Glucksberg et al. 21 The score was decreased by one stage when there were other causes, such as drug reactions and infections, that might contribute to the clinical signs of skin, gut or liver. 22 Antimicrobial prophylaxis consisted of 500 mg ciprofloxacin given twice daily and 500 mg valaciclovir given three times daily. Fluconazole was only given at a dose 200 mg per day orally to those who were considered colonized by Candida albicans. Patients received trimethoprim-sulphamethoxazole 480 mg per day orally at discharge, as prophylaxis against infections due to Pneumocystis jiroveci.
Twice weekly blood was drawn for aerobic culture from each lumen of the CVC. A blood culture was considered positive if a micro-organism was recovered from one or more bottles, with the exception of coagulase-negative staphylococci (CoNS), for which two separate positive blood cultures with the same strain were required. 23 At the onset of fever, defined as an axillary temperature X38.5 1C, 9 (14) 1 (5) Abbreviations: HSCT ¼ haematopoietic stem cell transplantation; MPS ¼ myeloproliferative syndromes. The study group consisted of 85 HSCT recipients and their donors. All received an HLA matched sibling depleted HSCT following conditioning with an idarubicin-containing regimen. GVHD prophylaxis consisted of CsA only. Characteristics are expressed in absolute numbers and percentage. Age is expressed as mean value with the total range. Differences between the study groups were compared using the Pearson's w 2 -test or Fisher's exact test and with the use of the independent t-test.
empirical therapy was started with 2000 mg ceftazidime given three times daily i.v. after blood cultures were obtained from each catheter lumen as well as from peripheral blood. Twenty-four patients (n ¼ 24) had received meropenem pre-emptively starting the day of HSCT.
Genotyping for NOD2 polymorphisms DNA from patients and donors was extracted by standard procedures (QIAamp DNA blood mini kit; Qiagen) from peripheral blood cells collected before HSCT. Patients and their donors had given their informed consent to the prospective collection of DNA samples for investigational use. We assayed SNP8 (Arg702Trp), 12 (Gly908Arg) and 13 (Leu1007fsinsC) using a real-time TaqMan PCR. Control samples that had been confirmed by sequencing were kindly supplied by Dr E Holler and J Brenmoehl (University Hospital of Regensburg). Probes and primers were synthesized by Applied Biosystems (Lingley House, Warrington, UK), with reporter dye 6-FAM or VIC linked at the 5 0 -end and the quencher dye TAMRA at the 3 0 -end. The final reaction mixture of 50 ml consisted of Master Mix (MgCl 2 5 mM, 10 Â TaqMan buffer 5 ml, dNTP 250 mM, AmpliTaq Gold 1.25 mU), 300 nM of each forward and reverse primer, 200 nM of each fluorescent probe and 50 ng of DNA. PCR amplification and fluorescence detection were achieved using an ABI Prism 7700 (Applied Biosystems).
Statistical analysis
We used descriptive statistics for the study group characteristics regarding the HSCT with values expressed in absolute numbers and percentage. Differences between patient/donor pairs with and without NOD2 polymorphisms were compared using the Pearson's w 2 -test or Fisher's exact test for proportions and with the independent t-test for numerical data (SPSS version 14.0).
The outcome variables aGVHD, TRM at 1 year (1-year TRM) and the occurrence of bacteraemia were analysed in relation to NOD2 polymorphisms.
The time to clinical event (1-year TRM, aGVHD) was determined from the date of HSCT. The time span for aGVHD extended to day 100, and that for 1-year TRM to day 365 after HSCT. The incidence of bacteraemia was determined from start of chemotherapy (day À12) until 14 days after transplantation.
The cumulative incidence was estimated to reflect the competing risks of death within 100 days from other toxicities or relapse for aGVHD, death from relapse for TRM and treatment-related death within 14 days without bacteraemia. Groups were formed according to occurrence of any polymorphism vs wild type and polymorphisms in both patient and donor vs wild type to allow analysis of polymorphisms in relation to aGVHD and TRM. In the analysis of bacteraemia only recipient status was considered of importance and patients with a polymorphism were compared with wild types.
The Gray test was used to evaluate the differences between cumulative incidence curves in these groups. These differences were also quantified by calculating the hazard ratios (HR) that resulted from the Fine and Gray models that take into account competing risks. These models were also used to adjust these HRs for age of the patient and donor, gender combination, the underlying haematological disease and status at HSCT, the T-cell-depletion technique and the stem cell source. Because the study group was small we had to limit the number of variables included in the multivariable analysis to the risk factors most associated with aGVHD and TRM.
The competing risks analyses were performed using the cmprsk package of open source language R version 2.6.2 (www.r-project.org). P-value o0.05 was considered to indicate statistical significance.
Results
NOD2 polymorphism frequency
The frequency of any polymorphism among patients was 16.5, and 21% among donors (Table 2) . Allele frequencies were 6.2, 0.6 and 3.2% for SNP8, 12 and 13 respectively, similar to the general Dutch population (5.9, 0.7 and 1.9). 24 There were four pairs (4.7%) in which only the patient, eight pairs (9.4%) in which only the donor and ten pairs (11.8%) in which both had an SNP. There were no significant differences in the characteristics of patient/ donor pairs with and without a polymorphism (Table 1) .
NOD2 polymorphisms and outcome
Acute GVHD. In the analysis of aGVHD four patients, one case with a polymorphism, were excluded because of death before engraftment. The overall incidence of aGVHD grade II-IV and grade III-IV was 32.1 and 7.4% respectively.
We first compared the incidence of aGVHD in pairs with any polymorphism present with the outcome of wild-type patient/donor pairs and found no significant difference in grade II-IV aGVHD (cumulative incidence 43 vs 30%, HR 1.5 95% CI: 0.7-4.6, P ¼ 0.30). However, an effect of NOD2 polymorphisms was seen for severe aGVHD with a cumulative incidence of 19% in pairs with any polymorphism compared to 3% for pairs with wild-type status (HR 6.0, 95% CI: 1.1-100, Gray test P ¼ 0.02). The magnitude of this difference was accounted for by the higher incidence of severe aGVHD in the subgroup of pairs in which both had a polymorphism, with an incidence of 33% (HR 10.5, 95% CI: 1.8-100, Gray test P ¼ 0.002; Figure 1 ). Furthermore, multivariable analysis, including patient and donor age, gender combination, stem cell source and T-celldepletion technique, showed that polymorphisms in NOD2 Table 2 Frequency of SNPs in patients and donors TRM and relapse. The overall 1-year TRM was 16.5%. The presence of a polymorphism was a significant factor with a cumulative incidence of 32% compared to 11% for wild-type status (HR 3.3, 95% CI: 1.2-9.1, Gray test P ¼ 0.02). Again this was mostly accounted for by patient/ donor pairs both bearing a polymorphism with an incidence of 50% (HR 5.9, 95% CI: 1.9-18.0, Gray test P ¼ 0.002; Figure 2 ). Mortality was predominantly attributed to aGVHD and infections, especially fungal infections.
In pairs with any polymorphism mortality was in 42.9% related directly to aGVHD compared to 0% for the wild types.
In multivariable analysis, including patient age and gender, underlying disease and disease status at HSCT, this impact remained with an HR of 3.8 for all polymorphisms and an HR of 7.8 for pairs both having a polymorphism.
No differences in the occurrence of disease relapse at 1-and 3-year follow-up were found in either univariable or multivariable analysis (data not shown).
Bacteraemia. Bacteraemia occurred in 68% of patients, with an incidence of bacteraemia due to CoNS of 45.9% and that due to oral viridans streptococci (OVS) of 25.9%. Analysis of the OVS bacteraemia was not possible as 24 patients had received meropenem. There was a cumulative incidence of CoNS bacteraemia until day 14 of 64.3 vs 36.6% (HR 1.85; 95% CI 0.95-3.60, P ¼ 0.07) among patients with a polymorphism compared to wild types.
Discussion
We show that there was a significant impact of NOD2 polymorphisms on treatment outcome, in particular severe aGVHD and TRM, among recipients of T-cell-depleted HSCT. The impact was most pronounced when both the patient and donor had an NOD2 polymorphism, suggesting that a 'continuous' NOD2 dysfunction in both epithelia and immune cells with subsequent defective antimicrobial activity and immune deregulation results in a worse clinical outcome. This finding was similar to the results reported by Holler et al. 6 However, the subgroups were too small to determine the impact when only a patient or donor had a polymorphism. Our data suggest that screening for NOD2 polymorphisms in this patient population could aid in improving the outcome after HSCT. This especially applies to the setting of HLA-identical sibling HSCT, because of a considerable chance of both patient and donor bearing a polymorphism, with significant consequences. Selecting a wild-type NOD2 sibling is preferred, but this might prove difficult because of the lack of matched siblings. Therefore, other approaches might be to select a voluntary unrelated donor without NOD2 polymorphisms or to adapt antimicrobial prophylaxis.
Our results contrast with those of Granell et al. 25 who found no impact of NOD2 polymorphisms on aGVHD and associated TRM in T-cell-depleted HSCT. There are several explanations for these different results. The most important is the higher overall incidence of aGVHD (grade II/IV, 32.1 vs 10%), which probably relates to the use of idarubicin-containing regimen, as this induces more MBI and aGVHD. 20 Furthermore, the use of partially T-celldepleted grafts, with a mean of 0.5 Â 10 6 CD3 þ T cells per kg, contributes to the higher incidence of aGVHD in our patients. There was also a higher allele frequency of NOD2 polymorphisms in our cohort (9.7 vs 5.1%). This results from true genetic heterogeneity between the Dutch and Spanish populations, 26 but could also be influenced by chance. Consistent with the increased incidence of severe aGVHD, in patients with NOD2 polymorphisms, TRM was related to aGVHD and infectious complications resulting from immunosuppressive therapy, especially fungal infections. No specific increase in mortality related to pneumonia was found contrary to the study of Granell et al. In the setting of HSCT using unrelated donors discrepancies in the impact of NOD2, polymorphisms on TRM and relapse have been attributed to the use of T-cell depletion with alemtuzumab (MabCampath) or not. 27 This underlines the necessity to take 'the context' of studies into account, especially with respect to the level of T-cell depletion and the overall incidence of aGVHD. As always, local data are required before adopting general conclusions and screening proposals.
We saw more bacteraemia due to CoNS in patients with an NOD2 polymorphism than was found among wild types, although the difference did not reach statistical significance. We were unable to determine the impact on bacteraemia due to OVS, because 24 patients had received meropenem and after correction the study group was too small to draw firm conclusions. NOD2 senses the cell wall constituent MDP, which is present in the Gramnegative and Gram-positive bacteria that colonize body surfaces or cause infection. NOD2 is important in the antibacterial defences especially by regulating the production of defensins at the epithelial barriers of gut and lung. 9, 28, 29 Defensins possess anti-staphylococcal and streptococcal activity 30 and, in the gut, are elaborated predominantly by Paneth cells. Their production has been shown decreased when there are NOD2 polymorphisms. 9, 10 The increased incidence of CoNS bacteraemia found in patients with an NOD2 polymorphism suggests that lower number or activity of the peptides influences infectious complications in HSCT. This might explain how the gut may be an important origin of staphylococcal and streptococcal bacteraemias. 31, 32 Consequently, polymorphisms in NOD2 predispose to infections with Gram-positive bacteria when patients are given prophylaxis with fluoroquinolones while suffering from MBI and lung epithelial damage.
Importantly, sensing bacteria or derived MDP by NOD2 has an impact on the incidence of aGVHD, since the impact of NOD2 polymorphisms on aGVHD disappears with the use of comprehensive prophylaxis. 33 MBI is induced by myeloablative conditioning therapy, 1 and is an inflammatory condition of the gut associated with the occurrence of aGVHD. 2, 3 Inflammation is exacerbated by the translocation of bacteria and microbial products that elaborate cytokine release through the stimulation of TLRs. In case of NOD2 polymorphism reduced defensin production could contribute to increased bacterial translocation. In addition, 'loss of tolerance' increases TLR activity and cytokine release. [13] [14] [15] [16] Consequently, reducing the microbial burden of the gut using antimicrobial prophylaxis that provides better Gram-positive and anaerobic coverage could prove beneficial for patients bearing an NOD2 polymorphism to reduce the risk of severe aGVHD and therewith TRM. This would especially apply to those patients in whom no wild-type donor can be selected.
The function of donor polymorphisms is less easy to explain, especially in the setting of T-cell depletion. However, donor immune cells can indirectly lower the production of defensins 34 and also suffer from the 'loss of tolerance', so they could influence incidence and severity of aGVHD.
Our study is limited by being of a retrospective nature and the fact that the study group was small. Nevertheless, in this very homogenous cohort of Dutch patients we were able to detect a significant impact of NOD2 polymorphisms in T-cell-depleted HSCT regarding severe aGVHD and TRM and showed a higher incidence of Gram-positive bacteraemia. We conclude that in our population NOD2 polymorphism screening should be used to optimize donor selection and antimicrobial prophylaxis to reduce the occurrence of aGVHD and TRM following allogeneic HSCT.
